{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T19:51:55Z","timestamp":1782417115504,"version":"3.54.5"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"DOI":"10.1186\/s13256-024-04793-9","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:01:41Z","timestamp":1727481701000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Management of anti-melanoma differentiation-associated gene 5 antibody-induced refractory dermatomyositis complicated by interstitial pneumonia using tofacitinib and its outcomes: a case report"],"prefix":"10.1186","volume":"18","author":[{"given":"Yui","family":"Imai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4151-9883","authenticated-orcid":false,"given":"Takafumi","family":"Yorozuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Nishimaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuru","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Kondoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Asai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Nishikiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Hosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,28]]},"reference":[{"key":"4793_CR1","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.3390\/medicina57121358","volume":"57","author":"TH Yen","year":"2021","unstructured":"Yen TH, Tseng CW, Wang KL, Fu PK. Combination therapy with rituximab, tofacitinib and pirfenidone in a patient with rapid progressive interstitial lung disease (RP-ILD) due to MDA5 antibody-associated dermatomyositis: a case report. Medicina. 2021;57:1358.","journal-title":"Medicina"},{"key":"4793_CR2","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/art.41105","volume":"72","author":"H Tsuji","year":"2020","unstructured":"Tsuji H, Nakashima R, Hosono Y, Imura Y, Yagita M, Yoshifuji H, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol. 2020;72:488\u201398.","journal-title":"Arthritis Rheumatol"},{"key":"4793_CR3","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1056\/NEJMc1900045","volume":"381","author":"Z Chen","year":"2019","unstructured":"Chen Z, Wang X, Ye S. Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med. 2019;381:291\u20133.","journal-title":"N Engl J Med"},{"key":"4793_CR4","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","volume":"57","author":"K Kurasawa","year":"2018","unstructured":"Kurasawa K, Arai S, Namiki Y, Tanaka A, Takamura Y, Owada T, et al. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatol. 2018;57:2114\u20139.","journal-title":"Rheumatol"},{"issue":"suppl 1","key":"4793_CR5","first-page":"9","volume":"9","author":"H Kawasumi","year":"2015","unstructured":"Kawasumi H, Gono T, Kawaguchi Y, Yamanaka H. Recent treatment of interstitial lung disease with idiopathic inflammatory myopathies. Clin Med Insights Circ Respir Pulm Med. 2015;9(suppl 1):9\u201317.","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"key":"4793_CR6","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1177\/0961203316651748","volume":"25","author":"R Nakashima","year":"2016","unstructured":"Nakashima R, Hosono Y, Mimori T. Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease. Lupus. 2016;25:925\u201333.","journal-title":"Lupus"},{"key":"4793_CR7","first-page":"5386797","volume":"2017","author":"Y Ogawa","year":"2017","unstructured":"Ogawa Y, Kishida D, Shimojima Y, Hayashi K, Sekijima Y. Effective administration of rituximab in anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease and refractory cutaneous involvement: a case report and literature review. Case Rep Rheumatol. 2017;2017:5386797.","journal-title":"Case Rep Rheumatol"},{"key":"4793_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010436","volume":"97","author":"Y Endo","year":"2018","unstructured":"Endo Y, Koga T, Suzuki T, Hara K, Ishida M, Fujita Y, et al. Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: a case report. Medicine. 2018;97: e0436.","journal-title":"Medicine"},{"key":"4793_CR9","first-page":"51","volume":"20","author":"H Ichiyasu","year":"2017","unstructured":"Ichiyasu H, Sakamoto Y, Yoshida C, Sakamoto K, Fujita R, Nakayama G, et al. Rapidly progressive interstitial lung disease due to anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis complicated with cervical cancer: successful treatment with direct hemoperfusion using polymyxin B-immobilized fiber column therapy. Respir Med Case Rep. 2017;20:51\u20134.","journal-title":"Respir Med Case Rep"},{"key":"4793_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.rmed.2016.10.019","volume":"121","author":"H Hozumi","year":"2016","unstructured":"Hozumi H, Fujisawa T, Nakashima R, Johkoh T, Sumikawa H, Murakami A, et al. Comprehensive assessment of myositis-specific autoantibodies in polymyositis\/dermatomyositis-associated interstitial lung disease. Respir Med. 2016;121:91\u20139.","journal-title":"Respir Med"},{"key":"4793_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.773352","volume":"12","author":"A Nombel","year":"2021","unstructured":"Nombel A, Fabien N, Coutant F. Dermatomyositis with anti-MDA5 antibodies: bioclinical features, pathogenesis and emerging therapies. Front Immunol. 2021;12: 773352.","journal-title":"Front Immunol"},{"key":"4793_CR12","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","volume":"51","author":"T Gono","year":"2012","unstructured":"Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatol (Oxf Engl). 2012;51:1563\u201370. https:\/\/doi.org\/10.1093\/rheumatology\/kes102.","journal-title":"Rheumatol (Oxf Engl)"},{"key":"4793_CR13","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s12016-020-08786-6","volume":"59","author":"H You","year":"2020","unstructured":"You H, Xu D, Zhao J, Li J, Wang Q, Tian X, et al. JAK inhibitors: prospects in connective tissue diseases. Clin Rev Allergy Immunol. 2020;59:334\u201351.","journal-title":"Clin Rev Allergy Immunol"},{"key":"4793_CR14","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00296-021-04819-1","volume":"41","author":"P Mehta","year":"2021","unstructured":"Mehta P, Machado PM, Gupta L. Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry. Rheumatol Int. 2021;41:1021\u201336.","journal-title":"Rheumatol Int"},{"key":"4793_CR15","volume":"14","author":"H Horiuchi","year":"2022","unstructured":"Horiuchi H, Utada S, Shinomiya Y, Miyagawa T, Sogo A, Niida S, et al. Chronic pulmonary aspergillosis during convalescence from severe COVID-19 treated with oral itraconazole: a report of two cases. Cureus. 2022;14: e27281.","journal-title":"Cureus"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-024-04793-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-024-04793-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-024-04793-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:01:57Z","timestamp":1727481717000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-024-04793-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,28]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4793"],"URL":"https:\/\/doi.org\/10.1186\/s13256-024-04793-9","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,28]]},"assertion":[{"value":"27 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The need for approval was waived by our ethics review board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"471"}}